Abstract
Each year, a huge number of new cases accounts of TB with added problems due to multidrug resistant TB varieties. Globally, TB is one of the top causes of loss of life among people living with HIV who are more likely than others to get TB infection. Current TB treatment includes long term administration of cocktail of drugs; hence, the development of an alternative armamentarium against TB is the primary requirement. In fact, new drugs with novel activity against mycobacteria are of significant importance in order to combat existing levels of resistance. The present report covers the discovery of a diarylquinoline TB drug, bedaquiline, its antituberculosis effects and mode of action. Clinical studies conducted on bedaquiline which brought it to the accelerated FDA acceptance have been described. This report is of great attention for therapeutic apothecaries working in TB medication growth in terms of creating further diarylquinoline applicants with a wide variety of antimycobacterial results.
Keywords: Antituberculosis drug, bedaquiniline, clinical trials, docking, diarylquinolone, Mycobacterium tuberculosis.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Bedaquiline: A New Hope to Treat Multi-Drug Resistant Tuberculosis
Volume: 14 Issue: 16
Author(s): Rahul V. Patel, Sd. Riyaz and Se Won Park
Affiliation:
Keywords: Antituberculosis drug, bedaquiniline, clinical trials, docking, diarylquinolone, Mycobacterium tuberculosis.
Abstract: Each year, a huge number of new cases accounts of TB with added problems due to multidrug resistant TB varieties. Globally, TB is one of the top causes of loss of life among people living with HIV who are more likely than others to get TB infection. Current TB treatment includes long term administration of cocktail of drugs; hence, the development of an alternative armamentarium against TB is the primary requirement. In fact, new drugs with novel activity against mycobacteria are of significant importance in order to combat existing levels of resistance. The present report covers the discovery of a diarylquinoline TB drug, bedaquiline, its antituberculosis effects and mode of action. Clinical studies conducted on bedaquiline which brought it to the accelerated FDA acceptance have been described. This report is of great attention for therapeutic apothecaries working in TB medication growth in terms of creating further diarylquinoline applicants with a wide variety of antimycobacterial results.
Export Options
About this article
Cite this article as:
Patel V. Rahul, Riyaz Sd. and Park Won Se, Bedaquiline: A New Hope to Treat Multi-Drug Resistant Tuberculosis, Current Topics in Medicinal Chemistry 2014; 14 (16) . https://dx.doi.org/10.2174/1568026614666140929114822
DOI https://dx.doi.org/10.2174/1568026614666140929114822 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Balancing Act between Colonisers and Inflammation: T regulatory and TH17 Cells in Mucosal Immunity during Otitis Media
Current Immunology Reviews (Discontinued) Translation Controlled mRNAs: New Drug Targets in Infectious Diseases?
Infectious Disorders - Drug Targets In silico Analysis of Toxins of Staphylococcus aureus for Validating Putative Drug Targets
Infectious Disorders - Drug Targets Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Surreptitious TB Infections with Recently Identified DM People: A Cross- Sectional Study
Infectious Disorders - Drug Targets Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics Antibiotic Properties of Novel Synthetic Temporin A Analogs and a Cecropin A-Temporin A Hybrid Peptide
Protein & Peptide Letters Back Pain in Children and Adolescents: Etiology, Clinical Approach and Treatment
Current Pediatric Reviews Alcohol Abuse and HIV Infection: Role of DRD2
Current HIV Research Recent Advances in Tuberculosis Vaccine Development
Current Respiratory Medicine Reviews Marine Sponges: Potential Sources of New Antimicrobial Drugs
Current Pharmaceutical Biotechnology Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry New Vaccines and Delivery Strategies for Adult Immunization
Current Immunology Reviews (Discontinued) Mechanism of Bioactive Transfer through Liposomal Bilayers
Current Drug Targets Applications of Molecular Simulation in the Discovery of Antituberculosis Drugs: A Review
Protein & Peptide Letters Evaluation of Various Diagnostic Techniques for the Diagnosis of Pulmonary and Extra Pulmonary Tuberculosis at a Tertiary Care Center in North India
Infectious Disorders - Drug Targets <i>In Vitro</i> Evaluation of Immunogenicity of Recombinant OMP25 Protein Obtained from <i>Endemic Brucella</i> abortus Biovar 3 as Vaccine Candidate Molecule Against Animal Brucellosis
Protein & Peptide Letters Environmental Factors Contributing to Susceptibility to Tuberculosis
Current Respiratory Medicine Reviews Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Alcohol Abuse, Immunosuppression, and Pulmonary Infection
Current Drug Abuse Reviews